arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Crinetics Pharmaceuticals, Inc.

CRNX
$84.96 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Crinetics Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $9.0B
Dividend Yield —
Revenue Growth 2336.3% ↘
Op. Margin None
ROIC -8.8% →
FCF / Share $-0.90 ↗
Trailing P/E —
Price / Book 7.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Aug 31, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$25.12M
↑ +2336.3% —
Net Income Profit after all expenses
$-120.86M
↓ -4.5% —
Operating Margin Operating profit as % of sales
-473.7%
↓ -27.7% —
FCF / Share Free cash flow per share
$-0.90
↑ +25.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
17
Cash Quality →
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 39 quarters